This led to the hypothesis that activation of the mTOR pathway promotes FADS2 overexpression by enhancing SREBP activity, thereby contributing to the resistance of bladder cancer cells to ferroptosis. This evidence concerns the gene MTOR and urinary bladder carcinoma.